Abstract / Summary
Hemodialysis can significantly prolong the survival of uremia patients, but uremia and long-term hemodialysis can also cause complications. This study aimed to compare the clinical efficacy between the menostat mesylate and sodium citrate as anticoagulants in patients receiving CRRT. The clinical data of 80 patients with uremic cerebral hemorrhage in our hospital from January 2020 to October 2022 were collected and randomly divided into observation (nelostat anticoagulation, n = 40) and control (citrate and sodium anticoagulation, n = 40) groups. Physiological parameters, CRRT filter life, coagulation function index, activated whole blood coagulation time (ACT), anticoagulation efficiency rate, and incidence of adverse reactions were compared between the two groups. The physiological index, coagulation function index, ACT value, and anticoagulation efficiency were higher in the observation group than in the control group (p < 0.05). The observation group also demonstrated a longer CRRT filter life and lower incidence of adverse reactions than those in the control group (both p < 0.5). Naphlimostat mesylate demonstrated a good anticoagulant effect and was safe for use in CRRT.
Primary Source
The International journal of artificial organs
Ask Prognia AI
Have questions about this randomised trial?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.